Precigen, Inc.
Financials
Valuation Metrics
Precigen, Inc.'s Market Cap is $2.47B. At end of 2025 it was $1.24B. Ranked #1869 of 3,116 in US market (top 60%), #684 of 1,472 on NASDAQ (top 46%), #116 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 44%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.47B | US#1,869/3,116 Sec#116/265 |
| Revenue | $86M | US#2,697/3,116 Sec#130/265 |
| Net Income | $-158M | US—/3,116 Sec—/265 |
| Total Assets | $170M | US#3,004/3,116 Sec#249/265 |
| Net Assets | $44M | US#2,857/3,116 Sec#224/265 |
| Employees | 160 | US#2,520/3,116 Sec#140/265 |
| Value | ||
| P/B | 56.78x | US#2,879/3,116 Sec#229/265 |
| P/S | 28.86x | US#2,877/3,116 Sec#153/265 |
| FCF Yield | -4.68% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROA | -92.61% | US#3,048/3,116 Sec#252/265 |
| Op. Margin | -46.08% | US#2,651/3,116 Sec#110/265 |
| Revenue Growth | 1875.50% | US#11/3,116 Sec#7/265 |
| Financial Health | ||
| Debt Ratio | 290.80% | US#2,076/3,116 Sec#208/265 |
| Total Debt | $98M | US#2,437/3,116 Sec#120/265 |
| FCF | $-116M | US#2,661/3,116 Sec#158/265 |
| Cash | $16M | US#2,888/3,116 Sec#258/265 |
| Current Ratio | 4.58x | US#513/3,116 Sec#154/265 |
| Performance | ||
| 1Y Return | 71.36% | US#349/3,116 Sec#65/265 |
| 1M Return | -18.93% | US#2,835/3,116 Sec#235/265 |
| From 52W High | -22.72% | US#1,835/3,116 Sec#114/265 |
| 1Y MDD | -40.50% | US#1,953/3,116 Sec#123/265 |
| Trading | ||
| Volume | 6,618,501 shares | US#227/3,116 Sec#16/265 |
| Trading Value | $45M | US#1,305/3,116 Sec#95/265 |
| Per Share | ||
| EPS | $-0.44 | US—/3,116 Sec—/265 |
| BPS | $0.12 | US#2,785/3,116 Sec#229/265 |
Company Info
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.